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be more important in the future. Although responents re-
ported their knowledge of pharmacoeconomics to be
good, a substantial lack of interest in caregiver burden
suggests that a large percentage of MCOs are still in a
silo model.
PDH5
HEALTH CARE EXPENDITURE IN AN HMO 
BEFORE AND AFTER AN EXCLUSIVE 
PHARMACY PARTNERSHIP
Peris A, Castiglione B, Vanscoy GJ
Stadtlander Operating Co., Pittsburgh, PA, USA
Stadtlanders Pharmacy focuses on the management of
high-cost, chronic illnesses by targeting numerous medi-
cation-optimizing initiatives towards patients and pre-
scribers. The cost impact of these initiatives has never
been measured in a controlled fashion. PURPOSE: The
purpose of this study is to assess the impact of an exclu-
sive pharmacy provider contract with a large HMO on
healthcare expenditures by a third party payor. This
analysis will evaluate per member per month (PMPM)
medical costs based on claims data prior to and following
a National Agreement that mandates exclusive pharmacy
services for HIV and transplant patients. METHODS: A
retrospective analysis of medical claims data was per-
formed for 40 patients from selected plans of a large, na-
tionwide HMO. Time frame for the analysis was 6
months prior to (1/97 to 6/97) and 6 months following
(1/98 to 6/98) an exclusive provider relationship with
Stadtlanders Pharmacy and the HMO. Inclusion criteria
consisted of transplant and HIV1 patients enrolled in the
third party plan from 1/97 to 6/98, who received immun-
osuppressants and antiretrovirals, respectively, from
Stadtlanders during the post-agreement time frame. Med-
ical claim submissions during the specified time periods
were analyzed to determine mean per-member-per-month
(PMPM) values. RESULTS: Nineteen transplant and 21
HIV patients were included in the analysis. Mean medical
PMPM prior to and following the National agreement
was $053 and $911, respectively for transplant patients
and $448 and $306, respectively for HIV patients. The
mean overall saving in medical costs was approximately
$140 PMPM for each disease state following the exclu-
sive contract with Stadtlanders Pharmacy. CONCLU-
SION: This analysis represents potential overall health-
care savings for certain chronic illnesses through an
exclusive partnership between a specialty pharmacy and
an HMO.
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OBJECTIVE: We assessed the usefulness of the French
hospital database (PMSI) implemented in view of a DRG-
like prospective payment system for an economic evaluation
of the management of haemophiliac patients. METH-
ODS: We extracted and analysed data of the French pub-
lic hospital database on hospitalizations with a principal
or secondary diagnosis of haemophilia (type A) for the
years 1996–1997. RESULTS: A total number of 7000
admissions were found per year. The inpatient admis-
sions concerned haematology and orthopaedic surgery
but were scattered over a total number of 328 DRGs, re-
flecting both the variability of practice patterns and more
likely of coding procedures. Almost all of DRGs have less
than 1% of the files registered. We identified 3 main am-
bulatory DRGs but none was specific to haemophilia.
The ambulatory DRGs contain more than 50% of the
files related to haemophilia. The analysis of the national
database does not permit to identify neither the type of
therapeutic strategy for haemophilia (prophylactic treat-
ment or on demand treatment) nor the presence of a factor
VIII inhibitor. We found differences on the quality of diag-
nostic coding between the regional university hospitals
(UH) and the local hospitals. The mean of diagnostics reg-
istered for patients in 1997 is 2.9 diagnostics in UH and 4
in other hospitals. We compared the observed costs of hae-
mophiliac patients with the DRG reimbursement schedule
and found variations from plus to minus 40%. This gap is
mainly explained by the length of hospitalization. Thus it
appeared that the national DRG database is not currently
appropriate for assessing the management and costs of
treatments for haemophiliac patients, but could well sup-
plement the existing prospective cohort studies.
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The impact of patient compliance/adherence on disease
management is well known. In order to improve compli-
ance with medication regimens health care providers
have counted pills, evaluated re-fill patterns, developed
electronic devices, used questionnaires to identify prob-
lem areas, yet compliance remains a significant barrier to
the effectiveness of medication regimens. OBJECTIVE:
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Was to evaluate whether a person’s beliefs regarding
where control over his health lies impacts his level of
compliance. METHOD: Data were collected on 460
DVA hyperlipidemia patients in a multisite DVA phar-
maceutical care study. Patients were given Form C of the
Multidimensional Health Locus of Control (MHLC).
Form C is an 18 item general purpose, condition-specific
locus of control scale consisting of 3 sub-scales, internal/
external control, chance and powerful others. Patients
were also given the Moriski Compliance Questionnaire
at visits 1, 5 and 7, and re-fill patterns were evaluated as
measures of compliance. RESULTS: Form C explains
16.1% of the variance in compliance (R2  0.161; P 
0.05). The internal/external control subscale R2  0.017;
P  0.05; the chance subscale R2  0.025; P  0.05; and
the powerful other subscale R2  0.155; P  0.001.
CONCLUSION: It is not surprising that the chance sub-
scale played little or no role in explaining the variance in
compliance, however we did expect the internal/external
control subscale to explain part of the variance. This
leads us to question whether the empowerment of pa-
tients improves compliance. Certainly, the impact of the
powerful others subscale suggests the opposite to be the
case. Patients with a high level of “powerful other” con-
trol were more likely to be compliant.
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Studies have demonstrated that subspecialists (SUBS)
provide better quality care when working within their
subspecialty as compared to primary care physicians
(PCPs). However, many SUBS care for patients outside of
their subspecialty. There are no data demonstrating that
SUBS treating patients outside of their specialty provide
worse care than PCPs or SUBS practicing within their
specialty. OBJECTIVES: Our purpose was to compare
the quality of care provided by SUBS practicing outside
of their subspecialty with PCPs and SUBS practicing
within their subspecialty. METHODS: We studied 5112
patients hospitalized with pneumonia (CAP), acute myo-
cardial infarction (AMI), congestive heart failure (CHF),
and upper gastrointestinal hemorrhage (UGIB) at 6 hos-
pitals in Cleveland. RESULTS: There were statistically
significant increases in severity-adjusted length of stay
(LOS) comparing SUBS practicing outside of specialty
with those practicing within specialty for patients with
CHF (23% increase, 95% CI 15%,32%), UGIB (22% in-
crease, 95% CI 7%,39%) and CAP (14% increase, 95%
CI 4%,24%). Severity-adjusted mortality (MORT) was
higher for all patients combined when comparing SUBS
outside of specialty with those within specialty (mortality
odds ratio 1.46, P  0.05). When comparing PCPs with
SUBs practicing outside of specialty, LOS was longer for
SUBs practicing outside of specialty for CHF (16% in-
crease, 95% CI 8%,26%), UGIB (15% increase, 95% CI
2%,30%), CAP (18% increase, 95% CI 9%,28%).
CONCLUSIONS: Our data suggest that SUBS caring for
patients outside of their subspecialty may have longer
LOS than SUBS practicing within specialty or PCPs, and
may have higher MORT. Our findings have implications
for health care systems where SUBS care for patients out-
side of their chosen subspecialty.
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OBJECTIVES: Most pharmacoeconomic studies concen-
trate mainly on drug costs and possibly, some additional
costs encountered in drug delivery when analysing over-
all hospital costs. Examination costs are mainly ignored
or, at best, estimated crudely. A flat rate is usually ap-
plied when calculating total therapy costs in hospitals.
METHODS: In this study, the total therapy costs of five
in-house non-surgical ENT treatments (30 patients in
each group) were calculated, with particular attention to
accurate personnel costing. Drug costs and examination
costs were examined independently. RESULTS: The total
therapy costs varied from $816 to $1562. Daily costs
varied from $170 to $186. Both examination costs and
drug costs were noted to amount to 25—28% of the total
therapy costs, but individual treatment analysis showed
wide variations in their relative contributions. For in-
stance in complicated otitis media examination costs
amounted 14.7% as compared to drug costs of 11.4%.
In contrast, in the treatment of sudden deafness, medica-
tion costs accounted for 2.5% of overall costs versus
24.6% of examination costs. CONCLUSIONS: Physi-
cians with cost responsibilities should be aware of the
differing contributions to overall costs from drug and ex-
amination costs. In detailed analysis, the relative contri-
butions from drug and examination costs can vary widely
but in our current study, the overall contribution from
these two categories was quite similar. Physicians should
be aware of the cost structure in different therapies so
that advantage may be taken of potential cost savings.
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